Cambiotics initiates first human clinical trial focused on PFAS reduction in firefighters with occupational PFAS exposure

Cambiotics ApS announced that it is developing beneficial bacteria intended to support the natural elimination of unwanted compounds, including PFAS, or “forever chemicals.” The available article text provides no efficacy data, launch timing, financial details, or market reaction.